4AOI

Crystal structure of C-MET kinase domain in complex with 4-(3-((1H- pyrrolo(2,3-b)pyridin-3-yl)methyl)-(1,2,4)triazolo(4,3-b)(1,2,4) triazin-6-yl)benzonitrile

4AOI の概要

• エントリーDOI: 10.2210/pdb4aoi/pdb
• 関連するPDBエントリー: 1FYR 1R0P 1R1W 1SHY 1SSL 1UX3 2CEW 2G15 2UZX 2UZY 2WD1 2WGJ 2WKM 3ZXZ 3ZZE 4AP7
• 分子名称: HEPATOCYTE GROWTH FACTOR RECEPTOR, 4-[3-(1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-[1,2,4]triazolo[4,3-b][1,2,4]triazin-6-yl]benzenecarbonitrile (3 entities in total)
• 機能のキーワード: transferase, kinase inhibitor
• 由来する生物種: HOMO SAPIENS (HUMAN)
• タンパク質・核酸の鎖数: 1
• 化学式量合計: 35231.77

構造登録者

McTigue, M.,Grodsky, N.,Ryan, K.,Cui, J.J. (登録日: 2012-03-27, 公開日: 2012-09-26, 最終更新日: 2023-12-20)

主引用文献

Cui, J.J.,Mctigue, M.,Nambu, M.,Tran-Dube, M.,Pairish, M.,Shen, H.,Jia, L.,Cheng, H.,Hoffman, J.,Le, P.,Jalaie, M.,Goetz, G.H.,Ryan, K.,Grodsky, N.,Deng, Y.,Parker, M.,Timofeevski, S.,Murray, B.W.,Yamazaki, S.,Aguirre, S.,Li, Q.,Zou, H.,Christensen, J.
Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (C-met) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-Ylmethyl)-1H-[1,2, 3]Triazolo[4,5-B]Pyrazin-6-Yl)-1H-Pyrazol-1-Yl)Ethanol (Pf-04217903) for the Treatment of Cancer.
J.Med.Chem., 55:8091-, 2012

PubMed Abstract: The c-MET receptor tyrosine kinase is an attractive oncology target because of its critical role in human oncogenesis and tumor progression. An oxindole hydrazide hit 6 was identified during a c-MET HTS campaign and subsequently demonstrated to have an unusual degree of selectivity against a broad array of other kinases. The cocrystal structure of the related oxindole hydrazide c-MET inhibitor 10 with a nonphosphorylated c-MET kinase domain revealed a unique binding mode associated with the exquisite selectivity profile. The chemically labile oxindole hydrazide scaffold was replaced with a chemically and metabolically stable triazolopyrazine scaffold using structure based drug design. Medicinal chemistry lead optimization produced 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol (2, PF-04217903), an extremely potent and exquisitely selective c-MET inhibitor. 2 demonstrated effective tumor growth inhibition in c-MET dependent tumor models with good oral PK properties and an acceptable safety profile in preclinical studies. 2 progressed to clinical evaluation in a Phase I oncology setting.

PubMed: 22924734
DOI: 10.1021/JM300967G

実験手法

X-RAY DIFFRACTION (1.9 Å)